Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancers.
Mehner C, Oberg AL, Kalli KR, Nassar A, Hockla A, Pendlebury D, Cichon MA, Goergen KM, Maurer MJ, Goode EL, Keeney GL, Jatoi A, Sahin-Tóth M, Copland JA, Radisky DC, Radisky ES.
Mehner C, et al. Among authors: radisky dc, radisky es.
Oncotarget. 2015 Nov 3;6(34):35737-54. doi: 10.18632/oncotarget.5927.
Oncotarget. 2015.
PMID: 26437224
Free PMC article.